Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
China-CHAMP phase 3 trial of low-dose atropine eye drops for slowing childhood myopia progression
CTR20213313Phase 3Completed
- Sponsor
- Zhaoke Ophthalmology
- Start
- Mar 2022
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of atropine in myopia (3 arms), sponsored by Zhaoke Ophthalmology. Primary endpoint: Between-group difference in change from baseline in cycloplegic autorefraction spherical equivalent at month 24 for 0.02% atropine versus placebo. Started Mar 2022; status: completed.
02
Drugs
atropine
03
Conditions
myopia
Beyond the preview
Go deeper on CTR20213313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213313.